Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,900 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 January 2022) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 6MB, 247 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 4 results:
Author Title [ Type(Asc)] Year
Filters: Author is Thuresson, M.  [Clear All Filters]
Journal Article
E. Rapsomaniki, Thuresson, M., Yang, E., Blin, P., Hunt, P., Chung, S. C., Stogiannis, D., Pujades-Rodriguez, M., Timmis, A., Denaxas, S. C., Danchin, N., Stokes, M., Thomas-Delecourt, F., Emmas, C., Hasvold, P., Jennings, E., Johansson, S., Cohen, D. J., Jernberg, T., Moore, N., Janzon, M., and Hemingway, H., Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction, Eur Heart J Qual Care Clin Outcomes, vol. 2, pp. 172-183, 2016.
M. A. Cavender, Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., Fu, A. Z., Bodegard, J., Blak, B. T., Wittbrodt, E., Thuresson, M., Fenici, P., Hammar, N., and Kosiborod, M., SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL, J Am Coll Cardiol, vol. 71, pp. 2497-2506, 2018.
M. Kosiborod, Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Thuresson, M., Arya, N., Bodegard, J., Hammar, N., and Fenici, P., Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo, Circulation, vol. 136, pp. 249-259, 2017.
H. J. L. Heerspink, Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Rodriguez, L. A. Garcia, Cea-Soriano, L., Kohsaka, S., Nicolucci, A., Lucisano, G., Lin, F. J., Wang, C. Y., Wittbrodt, E., Fenici, P., and Kosiborod, M., Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study, Lancet Diabetes Endocrinol, vol. 8, pp. 27-35, 2020.
[Page last reviewed 4 January 2022]